Arcus Biosciences annual net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Net Income Growth & History (RCUS)
Arcus Biosciences's net income was −$353.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$353.0M | −$70.0M | — |
| 2024 | 2024-12-31 | −$283.0M | $24.0M | — |
| 2023 | 2023-12-31 | −$307.0M | −$40.0M | — |
| 2022 | 2022-12-31 | −$267.0M | −$320.0M | — |
| 2021 | 2021-12-31 | $53.0M | $176.0M | — |
| 2020 | 2020-12-31 | −$123.0M | −$38.3M | — |
| 2019 | 2019-12-31 | −$84.7M | −$35.1M | — |
| 2018 | 2018-12-31 | −$49.6M | $3.5M | — |
| 2017 | 2017-12-31 | −$53.1M | −$35.1M | — |
| 2016 | 2016-12-31 | −$18.0M | — | — |
Arcus Biosciences quarterly net income
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$91.0M | −$91.0M | — |
| Q1 2026 | 2026-03-31 | −$128.0M | −$16.0M | — |
| Q4 2025 | 2025-12-31 | −$106.0M | −$12.0M | — |
| Q3 2025 | 2025-09-30 | −$135.0M | −$43.0M | — |
| Q2 2025 | 2025-06-30 | $0 | $93.0M | — |
| Q1 2025 | 2025-03-31 | −$112.0M | −$108.0M | — |
| Q4 2024 | 2024-12-31 | −$94.0M | — | — |
| Q3 2024 | 2024-09-30 | −$92.0M | −$21.0M | — |
| Q2 2024 | 2024-06-30 | −$93.0M | −$18.0M | — |
| Q1 2024 | 2024-03-31 | −$4.0M | $76.0M | — |
| Q3 2023 | 2023-09-30 | −$71.0M | −$6.0M | — |
| Q2 2023 | 2023-06-30 | −$75.0M | −$8.0M | — |
| Q1 2023 | 2023-03-31 | −$80.0M | −$12.0M | — |
| Q3 2022 | 2022-09-30 | −$65.0M | $13.0M | — |
| Q2 2022 | 2022-06-30 | −$67.0M | $9.0M | — |
| Q1 2022 | 2022-03-31 | −$68.0M | $4.6M | — |
| Q4 2021 | 2021-12-31 | $279.5M | $331.4M | — |
| Q3 2021 | 2021-09-30 | −$78.0M | −$79.8M | — |
| Q2 2021 | 2021-06-30 | −$76.0M | −$30.9M | — |
| Q1 2021 | 2021-03-31 | −$72.6M | −$44.8M | — |
| Q4 2020 | 2020-12-31 | −$51.9M | −$35.3M | — |
| Q3 2020 | 2020-09-30 | $1.8M | $24.2M | — |
| Q2 2020 | 2020-06-30 | −$45.1M | −$17.0M | — |
| Q1 2020 | 2020-03-31 | −$27.8M | −$10.1M | — |
| Q4 2019 | 2019-12-31 | −$16.6M | −$4.3M | — |
| Q3 2019 | 2019-09-30 | −$22.4M | −$11.5M | — |
| Q2 2019 | 2019-06-30 | −$28.1M | −$14.6M | — |
| Q1 2019 | 2019-03-31 | −$17.7M | −$4.7M | — |
| Q4 2018 | 2018-12-31 | −$12.3M | $915,000 | — |
| Q3 2018 | 2018-09-30 | −$10.8M | $12.3M | — |
| Q2 2018 | 2018-06-30 | −$13.5M | −$4.0M | — |
| Q1 2018 | 2018-03-31 | −$13.0M | −$5.8M | — |
| Q4 2017 | 2017-12-31 | −$13.2M | — | — |
| Q3 2017 | 2017-09-30 | −$23.1M | — | — |
| Q2 2017 | 2017-06-30 | −$9.6M | — | — |
| Q1 2017 | 2017-03-31 | −$7.2M | — | — |
Arcus Biosciences net income trends
Over the last five fiscal years, Arcus Biosciences's net income decreased from −$123.0M to −$353.0M, a change of −$230.0M. The latest reported quarter, Q2 2026, shows −$91.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
